Literature DB >> 31046116

The ubiquitinase ZFP91 promotes tumor cell survival and confers chemoresistance through FOXA1 destabilization.

Dong-E Tang1, Yong Dai1, Yong Xu1, Lie-Wen Lin1, Dong-Zhou Liu1, Xiao-Ping Hong1, Ming-Lin Ou1, Hao-Wu Jiang2, Song-Hui Xu1,3.   

Abstract

The forkhead box A1 (FOXA1), one of the forkhead class of DNA-binding proteins, functions as a transcription factor and plays a vital role in cellular control of embryonic development and cancer progression. Downregulation of FOXA1 has reported in several types of cancer, which contributes to cancer cell survival and chemoresistance. However, the mechanism for FOXA1 downregulation in cancer remains unclear. Here, we report that the ubiquitination enzyme zinc finger protein 91 (ZFP91) ubiquitinates and destabilizes FOXA1, which promotes cancer cell growth. High level of ZFP91 expression correlates with low level of FOXA1 protein in human gastric cancer (GC) cell lines and patient samples. Furthermore, ZFP91 knockdown reduces FOXA1 polyubiquitination, which decreases FOXA1 turnover and enhances cellular sensitivity to chemotherapy. Taken together, our findings reveal ZFP91-FOXA1 axis plays an important role in promoting GC progression and provides us a potential therapeutic intervention in the treatment of GC.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Year:  2020        PMID: 31046116     DOI: 10.1093/carcin/bgz085

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  7 in total

1.  Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91.

Authors:  Maha Hanafi; Xinde Chen; Nouri Neamati
Journal:  J Med Chem       Date:  2021-01-28       Impact factor: 7.446

2.  Targeting USP1-dependent KDM4A protein stability as a potential prostate cancer therapy.

Authors:  Shu-Zhong Cui; Zi-Ying Lei; Tian-Pei Guan; Ling-Ling Fan; You-Qiang Li; Xin-Yan Geng; De-Xue Fu; Hao-Wu Jiang; Song-Hui Xu
Journal:  Cancer Sci       Date:  2020-03-30       Impact factor: 6.716

Review 3.  E3 Ubiquitin Ligase in Anticancer Drugdsla Resistance: Recent Advances and Future Potential.

Authors:  Yuanqi Liu; Chaojun Duan; Chunfang Zhang
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

4.  ZFP91 is required for the maintenance of regulatory T cell homeostasis and function.

Authors:  Aiting Wang; Lei Ding; Zhongqiu Wu; Rui Ding; Xiao-Lu Teng; Feixiang Wang; Zhilin Hu; Lei Chen; Xiaoyan Yu; Qiang Zou
Journal:  J Exp Med       Date:  2021-02-01       Impact factor: 14.307

5.  ZFP91 promotes cell proliferation and inhibits cell apoptosis in AML via inhibiting the proteasome-dependent degradation of RIP1.

Authors:  Zhonghui Zhang; Liang Zhong; Wenran Dan; Xuan Chu; Chen Liu; Xu Luo; Peng Wan; Zhenyan Liu; Yang Lu; Xiao Wang; Beizhong Liu
Journal:  Int J Med Sci       Date:  2022-01-01       Impact factor: 3.738

6.  Breviscapine Participates in the Progression of Prostate Cancer by Inhibiting ZFP91 Expression through Upregulation of MicroRNA-129-5p.

Authors:  Jie Yang; Wanjun Jin; Xiaokang Zhang; Pengcheng Chang; Duo Zheng
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-08       Impact factor: 2.629

7.  Ginsenoside Rg3 increases gemcitabine sensitivity of pancreatic adenocarcinoma via reducing ZFP91 mediated TSPYL2 destabilization.

Authors:  Haixia Pan; Linhan Yang; Hansong Bai; Jing Luo; Ying Deng
Journal:  J Ginseng Res       Date:  2021-08-30       Impact factor: 5.735

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.